Drugs / KM-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05956314 | Mar 2023 → Nov 2024 | pachyonychia congenita, punctate palmoplantar keratoderma type 1 | Orvida Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05435638 | Jul 2022 → Sep 2024 | pachyonychia congenita, punctate palmoplantar keratoderma type 1 | Orvida Pharma | Completed | No outcome recorded |
| Phase 1 | NCT05454462 | May 2022 → Apr 2023 | neurodermatitis | Orvida Pharma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KM-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435638 ↗ |
| Action | Inhibit | “inhibition of TRPV3 by specific antagonists” NCT05956314 ↗ |
| Route | Topical | “with 1% topical KM-001” NCT05435638 ↗ |
| Target | TRPV3 | “a potent and selective TRPV3 antagonist” NCT05956314 ↗ |